<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03501043</url>
  </required_header>
  <id_info>
    <org_study_id>5075</org_study_id>
    <nct_id>NCT03501043</nct_id>
  </id_info>
  <brief_title>Assessment of Gait After Dysport Treatment</brief_title>
  <official_title>Video and Temporal Spatial Parameters Assessment of Gait After Dysport Treatment. A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein Healthcare Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albert Einstein Healthcare Network</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will aim to understand the potential benefit of the assessment of walking
      using video slow motion for muscle selection and the development of an image catalogue guide
      of the potential results of injection of abobotulinumtoxinA by comparing foot postures before
      and after injection. The objective is to evaluate the use of video assessment to improve
      muscle selection for the injection of botulinum toxin A to improve walking outcomes. Primary
      outcomes include: self-selected velocity (SSV), maximal velocity (MV) and symmetry of
      walking. Secondary outcomes include: passive range of motion (PROM), Modified Ashworth Scale
      (MAS) and the Tardieu Scale (TS). Fifteen persons post stroke or TBI over age 18 with
      equinovarus foot deformity who are able to ambulate will be included in the study. Dysport
      1000 to 1500 units will be used to be distributed on the basis of clinical indication to
      ankle plantar flexors (gastrocnemius and soleus), tibialis posterior and long toe flexors.
      The duration of subjects' participation is 4-6 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single arm, non-randomized clinical study with pre-post assessment to
      include post-stroke and Traumatic Brain Injury (TBI) outpatients with spastic ankle / foot
      muscles amenable to botulinum toxin injection. Subjects must be able to walk without braces.

      AbobotulinumtoxinA injection in a dose range of 500 to 1500 units one time to be distributed
      on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee
      extensors, knee flexors, tibialis posterior and long toe flexors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Actual">August 22, 2019</completion_date>
  <primary_completion_date type="Actual">August 22, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-Selected Velocity (SSV)</measure>
    <time_frame>Baseline, Follow-up (4-6 weeks)</time_frame>
    <description>Baseline and follow-up SSV with and without shoes. Distance covers over time at self selected pace. Larger value is better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal Velocity</measure>
    <time_frame>Baseline, Follow-up (4-6 weeks)</time_frame>
    <description>Baseline and follow-up MV with and without shoes. Distance covers over time when walking as fast as possible. Larger value is better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Step-length at Baseline and at Follow-up (Temporal-spatial Data)</measure>
    <time_frame>Baseline, Follow-up (4-6 weeks)</time_frame>
    <description>Step length measured as the distance between the heel contact point of one foot and that of the other foot.
Values are reported on the involved side. Larger values represent better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Ashworth Scale (MAS) at Baseline and at Follow-up</measure>
    <time_frame>Baseline, Follow-up (4-6 weeks)</time_frame>
    <description>Passive range of ankle in 1 second with knee flexed and knee extended. Scale of 0-4 (0: no increase in muscle tone; 1: Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension; 1+:Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM (range of movement); 2: More marked increase in muscle tone through most of the ROM, but affect part(s) easily moved; 3: Considerable increase in muscle tone passive, movement difficult; 4: Affected part(s) rigid in flexion or extension.
0-4 (Min-Max) Higher scores represents increase abnormal tone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tardieu Scale (TS) at Baseline and at Follow-up</measure>
    <time_frame>Baseline, Follow-up (4-6 weeks)</time_frame>
    <description>Measurement of spastic response when passively ranging the ankle joint at very slow and very fast velocities with knee flexed and knee extended.
Quality of muscle reaction (scored 0-4). 0 is no resistance to passive ROM to 4 indicating joint is immobile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Passive Range of Motion (PROM) at Baseline and at Follow-up</measure>
    <time_frame>Baseline, Follow-up (4-6 weeks)</time_frame>
    <description>Normal ranges of ankle dorsiflexion 0 to 30 degrees with knee flexed. Normal ranges of dorsiflexion 0 to 15 degrees with knee extended. Higher values in dorsiflexion range represent a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Equinovarus; Acquired</condition>
  <arm_group>
    <arm_group_label>Dysport</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 1000 to 1500 units of Dysport to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors for one injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dysport</intervention_name>
    <description>Dysport 1000 to 1500 units to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors.</description>
    <arm_group_label>Dysport</arm_group_label>
    <other_name>abobotulinumtoxinA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide signed and dated informed consent form

          -  Willing to comply with all study procedures and be available for the duration of the
             study

          -  Male or female, aged ≥ 18

          -  Equinovarus foot deformity appropriate for botulinum toxin treatment (naïve or
             non-naïve)

          -  Modified Ashworth Scale between 1 to 3

          -  Women of reproductive potential must use effective contraception for the duration of
             the study

        Exclusion Criteria:

          -  Inability to walk without leg brace

          -  Previous surgical intervention to affected/ankle/foot

          -  Uncontrolled seizures

          -  Pregnancy or lactation

          -  Known allergic reactions to Dysport

          -  Treatment with another investigational drug or other intervention in the past 4 months

          -  Modified Ashworth Scale 4

          -  Anything that would place the individual at increased risk or preclude the
             individual's full compliance with or completion of the study

          -  Lower motor neuron disorder

          -  &lt; Four months post botulinum toxin or serial casting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Esquenazi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MossRehab</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MossRehab</name>
      <address>
        <city>Elkins Park</city>
        <state>Pennsylvania</state>
        <zip>19002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <results_first_submitted>January 2, 2020</results_first_submitted>
  <results_first_submitted_qc>January 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein Healthcare Network</investigator_affiliation>
    <investigator_full_name>Alberto Esquenazi</investigator_full_name>
    <investigator_title>Chairman of Physical Medicine and Rehabilitation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clubfoot</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03501043/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03501043/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dysport</title>
          <description>All Participants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Post-stroke and TBI outpatients with spastic ankle / foot muscles amenable to botulinum toxin injection.</population>
      <group_list>
        <group group_id="B1">
          <title>Dysport</title>
          <description>All Participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>TBI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Paretic Side</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Left</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Self-Selected Velocity (SSV)</title>
        <description>Baseline and follow-up SSV with and without shoes. Distance covers over time at self selected pace. Larger value is better.</description>
        <time_frame>Baseline, Follow-up (4-6 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Barefoot SSV</title>
            <description>SSV reported in participants walking barefoot.</description>
          </group>
          <group group_id="O2">
            <title>Shoes SSV</title>
            <description>SSV reported in participants walking in shoes.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-Selected Velocity (SSV)</title>
          <description>Baseline and follow-up SSV with and without shoes. Distance covers over time at self selected pace. Larger value is better.</description>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread=".31"/>
                    <measurement group_id="O2" value=".48" spread=".27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread=".29"/>
                    <measurement group_id="O2" value="0.52" spread=".29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximal Velocity</title>
        <description>Baseline and follow-up MV with and without shoes. Distance covers over time when walking as fast as possible. Larger value is better.</description>
        <time_frame>Baseline, Follow-up (4-6 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Barefoot MV</title>
            <description>MV reported in participants walking barefoot.</description>
          </group>
          <group group_id="O2">
            <title>Shoes MV</title>
            <description>MV reported in participants walking in shoes.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Velocity</title>
          <description>Baseline and follow-up MV with and without shoes. Distance covers over time when walking as fast as possible. Larger value is better.</description>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".59" spread=".48"/>
                    <measurement group_id="O2" value=".71" spread=".41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".64" spread=".47"/>
                    <measurement group_id="O2" value=".78" spread=".44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Step-length at Baseline and at Follow-up (Temporal-spatial Data)</title>
        <description>Step length measured as the distance between the heel contact point of one foot and that of the other foot.
Values are reported on the involved side. Larger values represent better outcome.</description>
        <time_frame>Baseline, Follow-up (4-6 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Barefoot Step-Length</title>
            <description>Step-length reported in participants walking barefoot.</description>
          </group>
          <group group_id="O2">
            <title>Shoes Step-Length</title>
            <description>Step-length reported in participants walking in shoes.</description>
          </group>
        </group_list>
        <measure>
          <title>Step-length at Baseline and at Follow-up (Temporal-spatial Data)</title>
          <description>Step length measured as the distance between the heel contact point of one foot and that of the other foot.
Values are reported on the involved side. Larger values represent better outcome.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".47" spread=".30"/>
                    <measurement group_id="O2" value=".50" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".50" spread=".12"/>
                    <measurement group_id="O2" value=".51" spread=".14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Ashworth Scale (MAS) at Baseline and at Follow-up</title>
        <description>Passive range of ankle in 1 second with knee flexed and knee extended. Scale of 0-4 (0: no increase in muscle tone; 1: Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension; 1+:Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM (range of movement); 2: More marked increase in muscle tone through most of the ROM, but affect part(s) easily moved; 3: Considerable increase in muscle tone passive, movement difficult; 4: Affected part(s) rigid in flexion or extension.
0-4 (Min-Max) Higher scores represents increase abnormal tone.</description>
        <time_frame>Baseline, Follow-up (4-6 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MAS Ankle Knee Flexed</title>
            <description>Change in ankle knee flexion MAS score</description>
          </group>
          <group group_id="O2">
            <title>MAS Ankle Knee Extended</title>
            <description>Change in ankle knee extension MAS score</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Ashworth Scale (MAS) at Baseline and at Follow-up</title>
          <description>Passive range of ankle in 1 second with knee flexed and knee extended. Scale of 0-4 (0: no increase in muscle tone; 1: Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension; 1+:Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM (range of movement); 2: More marked increase in muscle tone through most of the ROM, but affect part(s) easily moved; 3: Considerable increase in muscle tone passive, movement difficult; 4: Affected part(s) rigid in flexion or extension.
0-4 (Min-Max) Higher scores represents increase abnormal tone.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.63" upper_limit="2"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.25" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tardieu Scale (TS) at Baseline and at Follow-up</title>
        <description>Measurement of spastic response when passively ranging the ankle joint at very slow and very fast velocities with knee flexed and knee extended.
Quality of muscle reaction (scored 0-4). 0 is no resistance to passive ROM to 4 indicating joint is immobile.</description>
        <time_frame>Baseline, Follow-up (4-6 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TS Ankle Knee Flexed Spasticity Grade</title>
            <description>Participants were measured by the muscles' responses to stretch at given velocities.</description>
          </group>
          <group group_id="O2">
            <title>TS Ankle Knee Extended Spasticity Grade</title>
            <description>Participants were measured by the muscles' responses to stretch at given velocities.</description>
          </group>
        </group_list>
        <measure>
          <title>Tardieu Scale (TS) at Baseline and at Follow-up</title>
          <description>Measurement of spastic response when passively ranging the ankle joint at very slow and very fast velocities with knee flexed and knee extended.
Quality of muscle reaction (scored 0-4). 0 is no resistance to passive ROM to 4 indicating joint is immobile.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="O2" value="3" lower_limit="3" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Passive Range of Motion (PROM) at Baseline and at Follow-up</title>
        <description>Normal ranges of ankle dorsiflexion 0 to 30 degrees with knee flexed. Normal ranges of dorsiflexion 0 to 15 degrees with knee extended. Higher values in dorsiflexion range represent a better outcome.</description>
        <time_frame>Baseline, Follow-up (4-6 weeks)</time_frame>
        <population>Clinician moved the ankle at flexion or extension with no effort from the participant.</population>
        <group_list>
          <group group_id="O1">
            <title>PROM Ankle Knee Flexed</title>
            <description>PROM measured at ankle knee flexed.</description>
          </group>
          <group group_id="O2">
            <title>PROM Ankle Knee Extended</title>
            <description>PROM measured at ankle knee extended.</description>
          </group>
        </group_list>
        <measure>
          <title>Passive Range of Motion (PROM) at Baseline and at Follow-up</title>
          <description>Normal ranges of ankle dorsiflexion 0 to 30 degrees with knee flexed. Normal ranges of dorsiflexion 0 to 15 degrees with knee extended. Higher values in dorsiflexion range represent a better outcome.</description>
          <population>Clinician moved the ankle at flexion or extension with no effort from the participant.</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" spread="13.3"/>
                    <measurement group_id="O2" value="34" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="7.8"/>
                    <measurement group_id="O2" value="45.7" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event was collected at follow-up (4-6 weeks) after the baseline visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dysport</title>
          <description>Participants that received Dysport.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stella Lee</name_or_title>
      <organization>MossRehab</organization>
      <phone>215-663-6665 ext 6665</phone>
      <email>leest@einstein.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

